Lecanemab-irmb: A Treatment Option for the Early Stages of Alzheimers Disease

Course overview

Over 55 million people are living with dementia worldwide and this number is expected to grow. The projections are that by 2050, the number of people with Alzheimers disease (AD) dementia will triple. These staggering numbers highlight the need for the development of new treatments for patients with AD. Lecanemab-irmb is a newly approved drug for AD patients with mild cognitive impairment or mild dementia. Further trials are needed to confirm the efficacy and safety of lecanemab in early AD. Pharmacy teams are well-positioned to discuss lecanemab-irmb with healthcare professionals and patients suffering from AD.